

Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7)

Scientific Organizers: Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff

March 19–23, 2017

Fairmont Chateau Whistler, Whistler, British Columbia, Canada

Sponsored by Astellas Pharma Inc., AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, Cell Signaling Technology, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche, Sangamo BioSciences, Inc., Takeda Pharmaceutical Company Limited and TESARO, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Meeting is full. Call for details or if you wish to be placed on a waitlist for the meeting.

BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. [Click here for more details.](#)

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our [policies](#).

**** Registration currently unavailable ****

No registration fees are used to fund entertainment or alcohol at this conference

Conference Program [Print](#) | [View meeting in 12 hr \(am/pm\) time](#)

The meeting will begin on Sunday, March 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 23 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 24 in order to fully experience the meeting.

SUNDAY, MARCH 19

16:00–20:00	Arrival and Registration	Macdonald Foyer
18:00–20:00	Welcome Mixer No registration fees are used to fund alcohol served at this function.	Macdonald Foyer

MONDAY, MARCH 20

07:00–08:00	Breakfast	Frontenac
08:00–09:30	Welcome and Keynote Session Registered attendees can view abstracts starting on 02/19/2017 Glenn Dranoff, Novartis Institutes for BioMedical Research, USA <i>Mechanisms of Protective Tumor Immunity</i> Andreas G. Plücker, University of Zürich, Switzerland <i>Past, Present and Future of Biologics</i> Coffee Break	Macdonald Ballroom
09:50–11:45	Multimodal Approaches to Immunotherapy Registered attendees can view abstracts starting on 02/19/2017 Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA <i>From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies</i> Robert D. Schreiber, Washington University School of	Macdonald Ballroom

Medicine, USA
Personalized Cancer Vaccines

Short Talk(s) Chosen from Abstracts

11:45–17:00	On Own for Lunch	
11:45–13:00	Poster Setup	Frontenac
13:00–22:00	Poster Viewing	Frontenac
16:30–17:00	Coffee Available	Macdonald Foyer
17:00–19:15	Immunosuppressive Cells in the Tumor Microenvironment Registered attendees can view abstracts starting on 02/19/2017	Macdonald Ballroom
	Alexander Y. Rudensky , HHMI/Memorial Sloan Kettering Cancer Center, USA <i>Tregs in Cancer Immunity</i>	
	Vincenzo Bronte , University of Verona, Italy <i>Role of Myeloid-Derived Suppressor Cells in Tumor Immunity</i>	
	Alberto Mantovani , Humanitas University, Italy <i>Role of Macrophages in Tumor Immunity</i>	
	Garry P. Nolan , Stanford University, USA <i>System Wide Order, from Disorder, at the Cancer-Immune Interface</i>	
19:15–20:15	Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.	Frontenac
19:30–22:00	Poster Session 1	Frontenac

TUESDAY, MARCH 21

07:00–08:00	Breakfast	Frontenac
08:00–11:00	Cancer Immunotherapy: Targeting Immune Checkpoints Registered attendees can view abstracts starting on 02/19/2017	Macdonald Ballroom
	Ira Mellman , Genentech, Inc., USA <i>PD-1/PD-L1</i>	
	Andrew D. Weinberg , Earle A. Chiles Research Institute/Oregon Health and Science University, USA <i>OX40 Agonists: Past, Present, and Future</i>	
	Coffee Break	
	Ana Carrizosa Anderson , Harvard Medical School, USA <i>Targeting Tim-3 in Cancer</i>	
	Randolph J. Noelle , Dartmouth College, USA <i>Targeting the VISTA Pathway in Oncology</i>	
	Short Talk(s) Chosen from Abstracts	
11:00–17:00	On Own for Lunch	
11:00–13:00	Poster Setup	Frontenac
13:00–22:00	Poster Viewing	Frontenac
16:30–17:00	Coffee Available	Macdonald Foyer
17:00–19:00	Cancer Immunotherapy: Combinatorial Approaches Registered attendees can view abstracts starting on 02/19/2017	Macdonald Ballroom

James P. Allison, University of Texas MD Anderson Cancer Center, USA
Inhibition of Immune Checkpoints

Sandra Demaria, Weill Cornell Medical College, USA
Radiotherapy Needs To Go Viral To Increase Responses To Checkpoint Inhibitors

Antoni Ribas, University of California, Los Angeles, USA
Overcoming Resistance to PD-1 Blockade Therapy

Short Talk Chosen from Abstracts

19:00–20:00	Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.	Frontenac
19:30–22:00	Poster Session 2	Frontenac

WEDNESDAY, MARCH 22

07:00–08:00	Breakfast	Frontenac
08:00–11:00	Cancer Immunotherapy: Cancer Vaccines that Work and Why Registered attendees can view abstracts starting on 02/19/2017 Elizabeth M. Jaffee , Johns Hopkins University, USA <i>Vaccine Based Combinatorial Immunotherapy Can Convert Pancreatic Cancers Into Immunologic Diseases</i> Cornelia L. Trimble , Johns Hopkins University School of Medicine, USA <i>Therapeutic HPV Vaccines; Testing Proof-of-Principle in Preinvasive Disease</i> Coffee Break Speaker to be Announced Ugur Sahin , TRON - Translationale Oncology, Germany <i>Individualizing Cancer Treatment by mRNA Therapies</i> Short Talk(s) Chosen from Abstracts	Macdonald Ballroom
11:00–17:00	On Own for Lunch	
11:00–13:00	Poster Setup	Frontenac
13:00–22:00	Poster Viewing	Frontenac
16:30–17:00	Coffee Available	Macdonald Foyer
17:00–19:00	Inflammation and the Tumor Microenvironment Registered attendees can view abstracts starting on 02/19/2017 Michael Karin , University of California, San Diego, USA <i>Immune Regulation of Liver Cancer: Chronic Hepatitis Promotes HCC Development by Dismantling Cancer Immunosurveillance</i> Shannon J. Turley , Genentech, Inc., USA <i>Leukocyte Function and Positioning in Diverse Stromal Niches</i> Thomas Gajewski , University of Chicago, USA <i>Tumor Intrinsic Mediators of Inflamed Versus Non-Inflamed Microenvironment</i> Short Talk Chosen from Abstracts	Macdonald Ballroom
19:00–20:00	Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.	Frontenac

19:30–22:00 **Poster Session 3** [Frontenac](#)**THURSDAY, MARCH 23**07:00–08:00 **Breakfast** [Frontenac](#)08:00–11:00 **Cancer Immunotherapy: Cellular Engineering** [Macdonald Ballroom](#)[Registered attendees](#) can view abstracts starting on 02/19/2017Philip D. Greenberg, University of Washington, USA
*Adoptive T Cell Therapy*Michel Sadelain, Memorial Sloan-Kettering Cancer Center, USA
*Signaling Modules that enhance CAR-T Therapy***Coffee Break**Carl H. June, University of Pennsylvania, USA
*CAR-T Therapy of ALL*Stanley R. Riddell, Fred Hutchinson Cancer Research Center/University of Washington, USA
*CAR-T Therapy of Solid Tumors***Short Talk(s) Chosen from Abstracts**11:00–17:00 **On Own for Lunch**16:30–17:00 **Coffee Available** [Macdonald Foyer](#)17:00–18:45 **Nex-Gen Technologies** [Macdonald Ballroom](#)[Registered attendees](#) can view abstracts starting on 02/19/2017**Speaker to be Announced**Lisa M. Coussens, Oregon Health & Science University, USA
*Method of Multiplex IHC Staining*Jim R. Heath, California Institute of Technology, USA
*Micro- and Nanotechnologies for Personalizing Cancer Immunotherapy*18:45–19:00 **Meeting Wrap-Up: Outcomes and Future Directions (Organizers)** [Macdonald Ballroom](#)[Registered attendees](#) can view abstracts starting on 02/19/201719:00–20:00 **Social Hour with Lite Bites** [Frontenac](#)

No registration fees are used to fund alcohol served at this function.

20:00–23:00 **Entertainment** [Frontenac](#)

Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

FRIDAY, MARCH 24**Departure**

*Session Chair †Invited, not yet responded.

Keystone Symposia thanks our Sponsors for generously supporting this meeting:





We gratefully acknowledge support for this conference from:

[Directors' Fund](#)

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

[Click here](#) to view all of the donors who support the Directors' Fund.

We gratefully acknowledge additional support for this conference from:



Cellcion, LLC



[Personalis Inc.](#)

We gratefully acknowledge additional in-kind support for this conference from those foregoing

speaker expense reimbursements:

Novartis Institutes for BioMedical Research

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

[Click here to view more of these organizations](#)

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

[Click here to view more of these organizations](#)

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: **Sarah Lavicka**, Assistant Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690

[Click here](#) for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact: **Yvonne Psaila**, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676